MPG.eBooks - Search Results - *

Cover Image

1

Pharmacoeconomic review report: Ivabradine hydrochloride (Lancora)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

2

Pharmacoeconomic review report: Sarilumab (Kevzara)

Published 2017

CADTH

Cover Image

3

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

4

Antibiotic impregnated cement for primary hip or knee arthroplasty : a review of the clinical and cost-effectiveness

Published 2015

Canadian Agency for Drugs and Technologies in Health

Cover Image

5

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Cover Image

6

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

7

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

8

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

9

Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) : indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myoc...

Published 2019

CADTH

Cover Image

10

Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

11

Pharmacoeconomic review report: Rivaroxaban (Xarelto) (Bayer Inc.) : indication : in combination with 75 mg to 100 mg acetylsalicylic acid (ASA), for the prevention of stroke, myoc...

Published 2019

CADTH

Cover Image

12

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Cover Image

13

Sensory rooms for patients with dementia in long-term care : clinical and cost-effectiveness, and guidelines

by Banerjee, Srabani, Ford, Caitlyn
Published 2018

CADTH

Cover Image

14

Pharmacoeconomic review report: Ivabradine hydrochloride (Lancora)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

15

Pharmacoeconomic review report: Upadacitinib (Rinvoq) (AbbVie) : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an ina...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

16

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication : adult patients with active psoriatic arthritis (PsA) who have respon...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

17

Pharmacoeconomic review report: Tocilizumab (Actemra) (Hoffman-La Roche Limited)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Cover Image

18

Pharmacoeconomic review report: Upadacitinib (Rinvoq) (AbbVie) : indication: for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an ina...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

19

Telehealth for patients with hypertension, coronary artery disease or implantable cardiac devices : a review of the clinical effectiveness, cost-effectiveness and guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

20

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...

Published 2018

Canadian Agency for Drugs and Technologies in Health

1
2